Atossa Therapeutics
ATOS
56 hedge funds and large institutions have $15.8M invested in Atossa Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 23 reducing their positions, and 22 closing their positions.
29% more call options, than puts
Call options by funds: $1.25M | Put options by funds: $971K
0.22% less ownership
Funds ownership: 1.23% → 1% (-0.22%)
23% less funds holding
Funds holding: 73 → 56 (-17)
38% less capital invested
Capital invested by funds: $25.4M → $15.8M (-$9.55M)
70% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 23
77% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
+$102K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$69.6K |
| 3 |
Two Sigma Investments
New York
|
+$57.3K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$24.5K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$21.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$866K |
| 2 |
Millennium Management
New York
|
-$837K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$676K |
| 4 |
D.E. Shaw & Co
New York
|
-$496K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$365K |
ATOS Hedge Fund Activity: Q3 2022 in Review
56 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2022, worth a combined $15.8M — down 38% from $25.4M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ATOS and 5 opened new positions — a net loss of 17 holders — while 23 trimmed existing stakes and 7 added.
The largest buyer was Mariner, opening a new position worth an estimated $102K. The largest seller was Renaissance Technologies, cutting an estimated $866K.
- 56 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2022, down from 73 in Q2 2022.
- Funds reported $15.8M of Atossa Therapeutics stock for Q3 2022, down 38% quarter-over-quarter.
- 5 funds opened new Atossa Therapeutics positions in Q3 2022 and 22 closed out, a net change of -17 holders.
- The largest Atossa Therapeutics buyer in Q3 2022 was Mariner, an estimated $102K added.
- The largest Atossa Therapeutics seller in Q3 2022 was Renaissance Technologies, an estimated $866K sold.
Based on aggregated 13F filings for Q3 2022.